Carregant...
Design and Evaluation of a CXCR4 Targeting Peptide 4DV3 as an HIV Entry Inhibitor and a Ligand for Targeted Drug Delivery
The feasibility of utilizing the cell surface chemokine receptor CXCR4 for human immunodeficiency virus (HIV) entry inhibition and as an intracellular portal for targeted drug delivery was evaluated. Novel DV3 ligands (1DV3, 2DV3, and 4DV3) were designed, synthesized and conjugated to various probes...
Guardat en:
| Publicat a: | Eur J Pharm Biopharm |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6286870/ https://ncbi.nlm.nih.gov/pubmed/29894816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejpb.2018.06.004 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|